Abstract
Oral pharmacotherapy is considered a first-line management option for erectile dysfunction (ED), yet many men discontinue the therapy, thereby requiring further intervention. Given US healthcare spending concerns, this cost analysis estimated the Medicare patient costs of guideline-recommended non-oral therapies for ED.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
Paper Title
Journal
Date
